In addition, USP22 was shown to induce cell cycle protein-dependent kinase inhibitor 1A (CDKN1A) in pancreatic cancer, and MDM2 inhibitors enhanced the anti-pancreatic cancer effect of USP22 overexpression [166]. This evidence concerns the gene USP22 and pancreatic neoplasm.